In 2017, Sonoma filed a lawsuit against Collidion, Hojabr Alimi, Sameer Harish, and Monica Shaffer in federal district court, alleging the misappropriation of its trade secrets and confidential and proprietary information relating to hypochlorous acid products.
| PETALUMA, Calif., Nov. 12, 2018 /PRNewswire/ -- Sonoma Pharma, Inc. (“Sonoma”) and Collidion, Inc. (“Collidion”) have today announced agreement to settle Sonoma’s claims of trade secret misappropriation and breaches of fiduciary duty against Collidion and certain of Collidion’s employees. In 2017, Sonoma filed a lawsuit against Collidion, Hojabr Alimi, Sameer Harish, and Monica Shaffer in federal district court, alleging the misappropriation of its trade secrets and confidential and proprietary information relating to hypochlorous acid products. As part of the settlement, Sonoma will dismiss this legal action without any admission of wrongdoing by any Defendant. There has been no finding of wrongdoing against any defendant. The agreement is to the satisfaction of all parties, but the terms of the settlement are otherwise being kept confidential. About Collidion Collidion, Inc. was founded in 2015 to improve the future of global healthcare through the delivery of innovative solutions that address significant unmet medical needs facing patient care. Collidion operates through subsidiaries, which we support through the infusion of capital, operational guidance, intellectual property and portfolio management, and commercial & business development expertise. Spectrum Antimicrobials, Inc. is focused on the development of several disruptive antimicrobial formulations for use in healthcare markets. These formulations are derived from novel and proprietary platform technologies intended to target antibiotic-resistant pathogens for the treatment and prevention of infections, sterilization of medical devices, disinfection of surfaces, and improvement of the food supply chain. The company is also developing the first novel blood filtration system for effective removal of bacterial proteins, endotoxins and pathogens responsible for causing sepsis in patients. Plex Pharmaceuticals has developed a number of proprietary, drug candidates to treat complex degenerative diseases caused by protein misfolding. Plex’s targeted molecules are intended for the following indications: non-surgical cataracts & presbyopia, glioblastoma, and Parkinson’s disease. Plex has also developed a novel drug candidate, which does not become neutralized in presence of blood or serum, intended to treat bacterial and viral conjunctivitis. Plex has a rich pipeline of drug discovery programs and a dedicated scientific team. Founded in 2009, Plex’s drug discovery lab and operations are located in San Diego, California. Awayk Health, LLC., provides a platform of services for patients with sleep apnea, from screening, testing, to treatment and compliance. Under distribution agreements with Philips Respironics and other manufacturers, Awayk provides CPAP machines directly to patients. Awayk has plans to commercialize Spectrum’s proprietary products for the daily cleansing and disinfection of CPAP machines.
SOURCE Collidion, Inc. |
View original content:
